Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 9/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 4/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1504744 | 0.90 | RORC (0.45) | RORCCYP3A4CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL375794 | 0.87 | ALDH1A1 (0.41) | RORCCYP3A4CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL1504505 | 0.82 | HDAC1 (0.48) | CYP1A2 | |
| SCHEMBL1504750 | 0.81 | LMNA (0.49) | CYP3A4CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL1504495 | 0.80 | TTR (0.46) | RORCCYP3A4CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL375290 | 0.80 | SLC22A12 (0.40) | RORCCYP2C9CYP1A2 | |
| SCHEMBL1504567 | 0.79 | L3MBTL1 (0.47) | — | |
| SCHEMBL375198 | 0.78 | ALDH1A1 (0.47) | CYP3A4CYP1A2CA12CA1CA9 | |
| SCHEMBL16672424 | 0.78 | ALDH1A1 (0.46) | NOTUM | |
| SCHEMBL1504556 | 0.77 | LMNA (0.39) | RORCCYP3A4CYP2C9CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173684-B2 | Pyridone derivatives as p38α MAPK inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-05-08 | — | — | US | disclosed |
| EP-1810972-B1 | NITROGENOUS HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2012-01-25 | — | — | EP | disclosed |
| EP-2155683-B1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-7713998-B2 | Nitrogenous heterocyclic compound and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20100063098-A1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20070265308-A1 | Nitrogenous Heterocyclic Compound and Pharmaceutical Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1810972-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265308-A1 | Nitrogenous Heterocyclic Compound and Pharmaceutical Use Thereof | MAPK1, MAPK13, MAPK6 | RORC 274/4885CYP3A4 863/4885CYP2C9 678/4885 |
| US-20100063098-A1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | MAPK1, MAPK6, MAPK3 | RORC 861/4885CYP3A4 743/4885CYP2C9 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.